Welcome to our dedicated page for Windtree Therapeutics news (Ticker: WINT), a resource for investors and traders seeking the latest updates and insights on Windtree Therapeutics stock.
Windtree Therapeutics, Inc. (WINT) reports developments tied to its transition from a biotechnology-focused company toward a diversified, revenue-generating operating model. Company news has covered material agreements involving cardiovascular drug candidates, licensing activity for acute pulmonary treatments, patent estate updates for istaroxime and SERCA2a activators, and clinical or regulatory disclosures related to heart failure and surfactant-based programs.
Recurring updates also include stockholder approvals, governance matters, capital actions, OTC trading status, and operating and financial results. Windtree’s disclosed product and license references include SURFAXIN®, lyophilized lucinactant, and AEROSURF®, a drug-device combination based on aerosolized KL4 surfactant delivery.
Windtree Therapeutics, Inc. (NasdaqCM: WINT) reported its financial results for Q4 and the fiscal year ending December 31, 2022. For Q4, the company reduced its operating loss to $10.8 million from $14.7 million in Q4 2021. The net loss was $9.7 million ($13.01 per share) compared to $13.1 million ($23.22 per share) the previous year. R&D expenses fell to $1.2 million in Q4 2022 from $4.5 million in Q4 2021, primarily due to focused resource allocation on the istaroxime pipeline. The company also issued a new patent for istaroxime, signaling advancement in its cardiovascular treatment efforts.
Windtree Therapeutics, Inc. (NasdaqCM: WINT) announced that it has regained compliance with Nasdaq's minimum bid price requirement, as detailed in a Bid Price Compliance Letter received on March 13, 2023. The company had previously fallen below the $1.00 bid price threshold, receiving a notification on June 3, 2022. However, Windtree successfully maintained a closing bid price above $1.00 for ten consecutive trading days, achieving compliance with Nasdaq Listing Rule 5550(a)(2). This milestone supports Windtree's ongoing development of cardiovascular interventions, including istaroxime for acute heart failure.
Windtree Therapeutics, Inc. (NasdaqCM: WINT) announced findings from a market study highlighting the substantial healthcare costs and lengthy hospital stays associated with cardiogenic shock. Data reveals an average hospital stay of 19.6 days, significantly higher than the 5.5 days average for all hospitalizations. The company is focusing on its drug candidate, istaroxime, which demonstrated promising results in a Phase 2 study, showing improved systolic blood pressure in treated patients. Market research indicates a strong need for innovation, with 99% of surveyed cardiologists acknowledging the need for new treatments, and 84% expressing willingness to prescribe istaroxime.
Windtree Therapeutics (NasdaqCM: WINT) announced that its SERCA2a activators were featured in a publication in The Journal of Pharmacology and Experimental Therapeutics. This highlights the potential of these drugs in treating heart failure by selectively targeting SERCA2a, which plays a crucial role in calcium management in heart muscles. The company emphasized the promising results from human clinical trials for its lead compound, istaroxime, which has shown positive outcomes in phase 2 studies for acute heart failure. Additionally, the USPTO published a new patent application related to SERCA2a activators, enhancing Windtree's intellectual property portfolio.
Windtree Therapeutics, Inc. (WINT) is advancing its drug candidate, istaroxime, targeting cardiogenic shock. The company announced acceptance of their abstract on istaroxime's safety and efficacy for presentation at the Technology and Heart Failure Therapeutics Conference from March 20-22, 2023. Data from the SEISMiC Phase 2 study showed that istaroxime significantly improved systolic blood pressure (SBP) over six hours and maintained this improvement through the 24-hour mark. No increase in cardiac arrhythmias was observed, indicating a potentially valuable therapy for heart failure. The analysis will further detail dose-specific data at the conference.
Windtree Therapeutics (WINT) has announced the issuance of U.S. Patent No. 11,583,540, extending patent protection for its investigational drug, istaroxime, until late 2039. Istaroxime is being studied for acute heart failure and cardiogenic shock, showcasing a dual mechanism that enhances both heart contraction and relaxation. The new patent allows for longer infusion durations, improving treatment outcomes. The CEO emphasized the drug's unique benefits compared to existing treatments. This strategic move strengthens Windtree's intellectual property portfolio as it advances its late-stage cardiovascular interventions.
Windtree Therapeutics, Inc. (NASDAQ: WINT) announced a 1-for-50 reverse stock split effective February 24, 2023. The decision, approved by stockholders on February 7, 2023, aims to increase the stock price to meet the $1 minimum bid requirement for The Nasdaq Capital Market. As a result, approximately 44.5 million shares will reduce to 0.9 million shares, with proportional adjustments to stock options and warrants. The reverse split will not impact stockholders' percentage ownership, and fractional shares will be rounded up. Continental Stock Transfer & Trust Company acts as the transfer agent for the split.
Windtree Therapeutics, Inc. (NASDAQ: WINT) announced on January 20, 2023, a warrant inducement offer to raise approximately $1.0 million by exercising warrants for 4,808,595 shares of common stock. The exercise price of certain previously issued warrants was reduced to $0.20 per share from prices as high as $12.09. In conjunction, new warrants to purchase 9,617,190 shares at $0.2152 will be issued. Completion of this transaction is expected to bolster the company’s capital before fees. The new warrants will be exercisable in six months and will expire in five years. The offerings are conducted through a private placement to accredited investors, exempt from registration requirements.
Windtree Therapeutics (WINT) announced an extension from Nasdaq, granting an additional 180 days to comply with the $1.00 minimum bid price requirement. This period extends until May 29, 2023. If WINT’s shares close at or above $1.00 for 10 consecutive days, it will regain compliance. The company may also opt for a reverse stock split to meet this requirement. Failure to comply by the deadline may lead to delisting, but it can appeal such a decision. Currently, the notification does not affect the trading status of WINT shares on Nasdaq.
Windtree Therapeutics (NasdaqCM: WINT) reported its Q3 2022 financial results, reflecting an operating loss of $4.7 million, a significant reduction from $8.1 million in Q3 2021. R&D expenses fell to $1.5 million, down from $4.7 million, focusing resources on istaroxime development after a successful SEISMiC study. The company announced a global license agreement with Lee's Pharmaceutical, potentially yielding up to $78.9 million. Cash and equivalents were $8.4 million, expected to fund operations into Q2 2023. Positive results in istaroxime studies were published, and a new patent was allowed by the USPTO.